ClinicalTrials.gg
CompletedNCT07057271Updated Jul 9, 2025

A Study of CJC-1134-PC Injection in Patients With Type 2 Diabetes With Inadequately Controlled Blood Glucose Level After Metformin Monotherapy or Metformin in Combination With Insulin Secretagogues

A Phase 3 interventional study of CJC-1134-PC Injection and Placebo in Type 2 Diabetes Mellitus - Poor Control, sponsored by Changshan ConjuChem BioPharmaceutical Research and Development (Hebei) Co., Ltd.. Completed at 1 site in China. Open to participants aged 18 Years to 70 Years. Per ClinicalTrials.gov, last updated 2025-07-09.

Sponsored by Changshan ConjuChem BioPharmaceutical Research and Development (Hebei) Co., Ltd. · Phase 3, Interventional, and Treatment

From the registry’s dates

  • Registered 4 years 1 month after the study started (first participant enrolled May 2021, registered Jun 2025).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
464
Allocation
Randomized
Ages
18 Years to 70 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 909 studies in Diabetes Mellitus, Type 2 with a site in China — 205 open to participants now, 228 under way, 46 of them phase 3. Diabetes Mellitus, Type 2 · China.

Enrollment
187th of 767
464 · median 199
Started
2021
with 56 others
Phase 3
207 of 909
38 open now
Registered
769th of 909
by date

Among the 909 studies in Diabetes Mellitus, Type 2 with a site in China, this one is the 187th largest by enrollment of the 767 interventional ones that give a count, is one of 57 that started in 2021, is one of 207 in phase 3, and was the 769th registered.

Diabetes Mellitus, Type 2

10,386 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,411 are open to participants now.

Browse Diabetes Mellitus, Type 2 studies →

Open to participants now

205 of the 909 studies in Diabetes Mellitus, Type 2 with a site in China are open now. Recruiting first, the newest first:

200 more — sign in →

All 205 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 883 Diabetes Mellitus, Type 2 studies recruiting now, 374 (42%) set no upper age limit and 383 (43%) stop at 75 or younger; 52 take children under 18; 205 take healthy volunteers.

This study: 18 Years to 70 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 909 studies in Diabetes Mellitus, Type 2 with a site in China, or all of them as a file.
02

Study summary

This study is a Multicenter, Randomized, Double-blind, Placebo-controlled Phase III Clinical Trial Designed to Evaluate the Efficacy and Safety of CJC-1134-PC Injection Administered Once A Week in Patients with Type 2 Diabetes with Inadequately Controlled Blood Glucose Level after Metformin Monotherapy or Metformin in Combination with Insulin Secretagogues.

03

Conditions studied

  • Type 2 Diabetes Mellitus - Poor Control
04

Who can participate

Ages eligible
18 Years to 70 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

Subjects were eligible for the study only if all the following inclusion criteria were met:

  1. Males or females aged 18 - 70 years (inclusive) at screening;
  2. Subjects with (BMI) ≥ 20 kg/ m2 and ≤ 40 kg/ m2.
  3. Patients with type 2 diabetes diagnosed according to the World Health Organization (WHO) 1999 criteria and who have received metformin monotherapy or metformin in combination with insulin secretagogues at stable doses for at least 2 consecutive months at screening (a daily dose of NLT 1,500 mg or a maximum tolerated dose and NLT 1,000 mg/day for metformin, and a dose of NLT half of the maximum dose as recommended in local IFU or the maximum tolerated dose for insulin secretagogues).
  4. Patients with stable living habits 2 months prior to screening, e.g., stable dietary habits and physical activities;
  5. Patients with the fasting plasma glucose or fasting serum glucose at the clinical site and the fasting plasma glucose in the central laboratory of NMT 13.9 mmol/L (250 mg/dL) at screening period; with the fasting plasma glucose in the central laboratory of NMT 13.9 mmol/L (250 mg/dL) at V3;
  6. Patients with the level of NLT 7.0% and NMT 11.0% at screening in local laboratory, and with the HbA1c level of NLT 7.0% and NMT 11.0% at screening and V3 in the central laboratory;
  7. Patients who were able to understand the procedures and methods of the study, willing to strictly comply with the clinical trial protocol, and voluntarily signed the form.

Exclusion criteria

Exclusion Criteria:

  1. Diagnosis of type 1 diabetes mellitus, or a specific type of diabetes mellitus caused by damage to the pancreas or other disease (such as acromegaly or Cushing syndrome);
  2. History of acute pancreatitis prior to screening or current history of acute or chronic pancreatitis.
  3. Active gallbladder or biliary tract disease within 1 year prior to screening (active refers to the presence of associated symptoms);
  4. Family or personal history of medullary thyroid cancer or multiple endocrine neoplasia type 2 (family refers to first-degree relatives by blood);
  5. Individuals with a history of malignant tumors within the previous 5 years, except patients with cured basal cell carcinoma of the skin and carcinoma in situ of the cervix;
  6. Decompensated cardiac dysfunction ( cardiac class III or IV) within 6 months prior to screening or currently;
  7. Myocardial infarction, coronary artery bypass grafting, coronary stenting, hemorrhagic or ischemic stroke (except lacunar cerebral infarction), or hospitalization for unstable angina or within 6 months prior to screening;
  8. Uncontrolled and severe cardiac dysrhythmia [e.g., second- or third-degree atrioventricular block, prolonged (QTc >450 ms)] within 6 months prior to screening and judged by the investigator to be unsuitable for participation in this trial;
  9. Severe diabetic neuropathy within 6 months prior to screening;
  10. History of diabetic foot ulcer within 1 year prior to screening;
  11. Proliferative diabetic retinopathy within 6 months prior to screening or at the time of screening [confirmed by fundus photography without mydriasis or by fundus examination with medicated mydriasis (unless mydriasis is ) by an eye health care provider, or a history of laser treatment for proliferative diabetic retinopathy within 6 months prior to screening];
  12. Diabetic ketoacidosis or hyperglycemic hyperosmolar state occurred within 6 months before screening to before randomization;
  13. History of 2 or more episodes of severe hypoglycemia within 6 months prior to screening or severe hypoglycemia between screening and pre-randomization (see Section 3.3.2.1 of version 1.2 of the protocol for definition of hypoglycemia);
  14. Previous (e.g., major or total gastrectomy, sleeve gastrectomy, gastric bypass) or current history of significant gastrointestinal disease (e.g., active ulcers, gastroparesis, pyloric obstruction, intestinal obstruction, inflammatory bowel disease, etc.) or chronic gastrastric-related surgery disease that requires long-term use of medications directly affecting gastrointestinal peristalsis and judged by the investigator to be unsuitable to participate in this trial;
  15. Severe trauma or moderate to major surgery within 1 month prior to screening and up to the time of randomization or the need for systemic use of anti-infective medications and, in the judgment of the investigator, the above conditions may affect glycemic control; Prohibited treatments and/or drugs
  16. Currently using weight-loss drugs, or the patient's weight has changed significantly (change NLT 10%) within 3 months before screening;
  17. Received treatment with glucose-lowering medications other than metformin or insulin secretagogue (including traditional Chinese medicine with glucose-lowering effects or glucose-lowering medications under clinical validation) within 3 months prior to screening;
  18. Continuous use of insulin treatment for more than 2 weeks within 1 year before screening (the time for gestational diabetes mellitus receiving insulin treatment is not within this limit);
  19. Prior treatment with a dipeptidyl peptidase 4 (DPP-4) inhibitor or glucose-dependent insulinotropic polypeptide (GIP) or glucagon-like peptide-1 (GLP-1) receptor agonist and discontinuation due to lack of safety and/or efficacy;
  20. Received treatment with any other product or device within 3 months prior to screening;
  21. Received systemic (other than inhaled or topical use) or growth hormone treatment within 3 months before screening;
  22. Being on warfarin at the time of screening and unable to discontinue it for the duration of the study; Laboratory findings
  23. Systolic blood pressure >160 mmHg and/or diastolic blood pressure >100 mmHg after 5 minutes of sedentary rest at screening or on the day of randomization [if the above criteria are met, the test can be repeated 2 more times (each time more than 1 minute apart) and the average of the 3 tests will be taken and judged again by the above criteria];
  24. Estimated (eGFR) \<60 mL/min or urine protein qualitative test NLT ++;
  25. (ALT) or/and aspartate aminotransferase (AST) >2.5 × (upper limit of normal range) or total level >1.5 × ULN (upper limit of normal range);
  26. Currently accompanied by thyroid dysfunction that cannot be controlled with a stable drug dose (referring to a stable dose for 4 weeks or more) or abnormalities of clinical meaningfulness in thyroid function test results (TSH, FT4, FT3) during screening;
  27. Currently suffering from anemia ( level in males \<120 g/L, females \<110 g/L)) or other conditions that interfere with testing;
  28. Fasting triglycerides >5.64 mmol/L (500 mg/dL);
  29. Serum amylase or serum lipase >3 × ULN (upper limit of normal range);
  30. surface antigen positive, antibodies positive or antibodies positive (weak positive is regarded as positive); Gender and reproductive status
  31. Positive pregnancy test result at screening;
  32. Pregnant or lactating female at enrollment;
  33. Female subjects of or male subjects whose sexual partner is a female of childbearing potential who are unwilling to use effective, medically approved (including condoms containing sperm-inactivated spermatozoa, vaginal septum, and oral or injectable contraceptives) during the study and for 3 months after discontinuation; Other criteria
  34. Alcoholics [>2 units of alcohol per day and >14 units of alcohol per week (1 unit of alcohol consumption is equivalent to 150 mL of wine or 350 mL of beer or 50 mL of spirits)] or a drug abuse history;
  35. Blood donation or transfusion NLT 400 mL within 3 months prior to screening;
  36. Intellectual disability or severe mental illness affecting the signing of or adherence to the study protocol;
  37. Known allergies to ebenatide, human albumin (the raw material for the ebenatide formulation), empagliflozin, or related ;
  38. Known intolerance to ebenatide or empagliflozin;
  39. Other circumstances that the investigator deems inappropriate for participation in this trial.
Terms in these criteria, in plain language(20)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
464 participants (actual)

Study arms

  • Experimental
    CJC-1134-PC

    Injection, 0.2ml/2mg (prefilled pen)

    Drug: CJC-1134-PC Injection

  • Placebo comparator
    Placebo

    Injection, 0.2ml/0mg (prefilled pen)

    Drug: Placebo

Interventions

  • Double-blind Treatment Period: 0.2ml (2mg) once weekly ×24 weeks (Week 1 to Week 24); Open-label Treatment Period: 0.2ml (2mg) once weekly ×28 weeks (Week 25 to Week 52)

  • DrugPlacebo

    Double-blind Treatment Period: 0.2ml (0mg) once weekly ×24 weeks (Week 1 to Week 24); Open-label Treatment Period: 0.2ml (2mg) once weekly ×28 weeks (Week 25 to Week 52)

06

What researchers measure

Primary outcomes

  1. Change from baseline in HbA1c at the end of double-blind treatment period

    The double-blind treatment period ended at the 25-week visit.

    Time frame: Week 25 visit

Secondary outcomes

  1. Proportion of subjects with HbA1c <7.0% at the end of the double-blind/open-label treatment period.

    The double-blind treatment period ended at the 25-week visit, and the open-label treatment period ended at the 53-week visit.

    Time frame: Week 25 visit, and week 53 visit.

  2. Proportion of subjects with HbA1c <6.5% at the end of the double-blind/open-label treatment period.

    The double-blind treatment period ended at the 25-week visit, and the open-label treatment period ended at the 53-week visit.

    Time frame: Week 25 visit, and week 53 visit.

  3. Changes from baseline in fasting weight at the end of double-blind/open-label treatment period.

    The double-blind treatment period ended at the 25-week visit, and the open-label treatment period ended at the 53-week visit.

    Time frame: Week 25 visit, and week 53 visit.

  4. Changes from baseline in fasting waist circumference at the end of double-blind /open-label treatment period.

    The double-blind treatment period ended at the 25-week visit, and the open-label treatment period ended at the 53-week visit.

    Time frame: Week 25 visit, and week 53 visit.

  5. Changes from baseline in fasting plasma glucose at the end of double-blind/open-label treatment period.

    The double-blind treatment period ended at the 25-week visit, and the open-label treatment period ended at the 53-week visit.

    Time frame: Week 25 visit, and week 53 visit.

  6. Changes from baseline in fasting proinsulin at the end of double-blind/open-label treatment period.

    The double-blind treatment period ended at the 25-week visit, and the open-label treatment period ended at the 53-week visit.

    Time frame: Week 25 visit, and week 53 visit.

  7. Changes from baseline in fasting insulin at the end of double-blind/open-label treatment period.

    The double-blind treatment period ended at the 25-week visit, and the open-label treatment period ended at the 53-week visit.

    Time frame: Week 25 visit, and week 53 visit.

  8. Changes from baseline in fasting C-peptide at the end of double-blind/open-label treatment period.

    The double-blind treatment period ended at the 25-week visit, and the open-label treatment period ended at the 53-week visit.

    Time frame: Week 25 visit, and week 53 visit.

  9. Changes from baseline in fasting lipids (total cholesterol) at the end of double-blind/open-label treatment period.

    The double-blind treatment period ended at the 25-week visit, and the open-label treatment period ended at the 53-week visit.

    Time frame: Week 25 visit, and week 53 visit.

  10. Changes from baseline in fasting lipids (low-density lipoprotein [LDL]) at the end of double-blind/open-label treatment period.

    The double-blind treatment period ended at the 25-week visit, and the open-label treatment period ended at the 53-week visit.

    Time frame: Week 25 visit, and week 53 visit.

  11. Changes from baseline in fasting lipids (high-density lipoprotein [HDL]) at the end of double-blind/open-label treatment period.

    The double-blind treatment period ended at the 25-week visit, and the open-label treatment period ended at the 53-week visit.

    Time frame: Week 25 visit, and week 53 visit.

  12. Changes from baseline in fasting lipids (triglycerides) at the end of double-blind/open-label treatment period.

    The double-blind treatment period ended at the 25-week visit, and the open-label treatment period ended at the 53-week visit.

    Time frame: Week 25 visit, and week 53 visit.

  13. Changes from baseline in fasting lipids (LDL/HDL ratio) at the end of double-blind/open-label treatment period.

    The double-blind treatment period ended at the 25-week visit, and the open-label treatment period ended at the 53-week visit.

    Time frame: Week 25 visit, and week 53 visit.

  14. Changes from baseline in systolic blood pressure [SBP] at the end of double-blind/open-label treatment period.

    The double-blind treatment period ended at the 25-week visit, and the open-label treatment period ended at the 53-week visit.

    Time frame: Week 25 visit, and week 53 visit.

  15. Changes from baseline in diastolic blood pressure [DBP] at the end of double-blind treatment period.

    The double-blind treatment period ended at the 25-week visit, and the open-label treatment period ended at the 53-week visit.

    Time frame: Week 25 visit, and week 53 visit.

  16. Changes from baseline in 6-point finger-stick blood glucose at the end of double-blind/open-label treatment period.

    The double-blind treatment period ended at the 25-week visit, and the open-label treatment period ended at the 53-week visit.

    Time frame: Week 25 visit, and week 53 visit.

  17. Changes from baseline in blood AST at the end of double-blind/open-label treatment period in patients diagnosed with fatty liver on screening imaging.

    The double-blind treatment period ended at the 25-week visit, and the open-label treatment period ended at the 53-week visit.

    Time frame: Week 25 visit, and week 53 visit.

  18. Changes from baseline in blood ALT at the end of double-blind/open-label treatment period in patients diagnosed with fatty liver on screening imaging.

    The double-blind treatment period ended at the 25-week visit, and the open-label treatment period ended at the 53-week visit.

    Time frame: Week 25 visit, and week 53 visit.

  19. Change from baseline in HbA1c at the end of open-label treatment period.

    The open-label treatment period ended at the 53-week visit.

    Time frame: Week 53 visit.

07

Study locations

1 site
  • Peking University People's Hospital
    Beijing, Beijing Municipality 100044, China
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from May 2021 to primary completion in Feb 2023, 20 months.

Of 438 industry-sponsored phase 3 interventional studies under Diabetes Mellitus, Type 2, half reached primary completion within 19 months of starting (the median), counting those still running; a quarter within 14 and three quarters within 26. This study's 20 months is close to that.

Counting every sponsor, half of 525 studies reached it within 20 months; a quarter within 14 and three quarters within 30.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 30, 2025
First posted
Jul 9, 2025
StartActual
May 27, 2021
Primary completionActual
Feb 21, 2023
CompletionActual
Feb 21, 2023
Last update
Jul 9, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 9, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07057271
Lead sponsor
Changshan ConjuChem BioPharmaceutical Research and Development (Hebei) Co., Ltd.
Responsible party
Sponsor
First posted
Jul 9, 2025
Start date
May 27, 2021
Primary completion
Feb 21, 2023
Completion
Feb 21, 2023
Last update
Jul 9, 2025

Study contacts

Linong Ji, Prof.
study chair · Peking University People's Hospital

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jun 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Albenatide

Start the discussion